Stocks · Health care · Biological Products, (No Diagnostic Substances)

EXELIXIS, INC.

EXEL Clue Score84
United States Fiscal year ends January CIK 0000939767 Results filed 29 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Mary C Beckerle
10 Aug 2026
Director
Sold on a plan
9,812
$53.66
$526.51K
Sue Gail Eckhardt
1 Jun 2026
Director
Sold on a plan
9,812
$50.14
$491.97K
Jack L Wyszomierski
1 Jun 2026
Director
Sold on a plan
3,925
$50.55
$198.41K
Dana Aftab
26 May 2026
EVP, Research and Development
Sell
43,451
$50.35
$2.19M
Patrick J. Haley
20 May 2026
EVP, Commercial
Sell
32,110
$49.81
$1.60M
Brenda Hefti
18 May 2026
SVP and General Counsel
Sold on a plan
6,625
$50.21
$332.64K
Christopher J. Senner
18 May 2026
EVP and CFO
Sell
34,901
$50.00
$1.75M
George Poste
7 May 2026
Director
Sell
60,000
$45.71
$2.74M
Maria C Freire
7 May 2026
Director
Sold after exercise
20,634
$46.00
$949.16K
Mary C Beckerle
7 May 2026
Director
Sold after exercise
7,712
$48.45
$373.65K
Dana Aftab
24 Feb 2026
EVP, Research and Development
Sell
47,918
$44.50
$2.13M
Dana Aftab
19 Feb 2026
EVP, Research and Development
Sell
29,873
$44.35
$1.32M
Brenda Hefti
18 Feb 2026
SVP and General Counsel
Sold on a plan
18,669
$44.01
$821.62K
Julie Smith
18 Feb 2026
Director
Sold after exercise
20,030
$44.30
$887.33K
Julie Smith
18 Feb 2026
Director
Sold after exercise
44,087
$44.50
$1.96M
Jack L Wyszomierski
18 Feb 2026
Director
Sold after exercise
99,574
$44.01
$4.38M
Patrick J. Haley
17 Feb 2026
EVP, Commercial
Sell
64,778
$43.50
$2.82M
Patrick J. Haley
17 Feb 2026
EVP, Commercial
Sell
3,036
$43.84
$133.10K
Christopher J. Senner
17 Feb 2026
EVP and CFO
Sell
30,617
$43.67
$1.34M
Julie Smith
17 Feb 2026
Director
Sold after exercise
42,422
$43.33
$1.84M
Bob Oliver
13 Feb 2026
Director
Sold after exercise
21,162
$43.90
$929.01K
Bob Oliver
13 Feb 2026
Director
Sold after exercise
9,088
$43.61
$396.33K
Sue Gail Eckhardt
13 Feb 2026
Director
Sold on a plan
3,856
$43.79
$168.85K
Michael Morrissey
13 Feb 2026
President and CEO
Exercised, kept
494,700
$21.31
$10.54M
Christopher J. Senner
13 Feb 2026
EVP and CFO
Sell
34,278
$43.00
$1.47M
David Edward Johnson
25 Nov 2025
Director
Buy indirect
27,532
$43.12
$1.19M
Patrick J. Haley
21 Nov 2025
EVP, Commercial
Sell
28,043
$42.58
$1.19M
Patrick J. Haley
20 Nov 2025
EVP, Commercial
Sell indirect
10,648
$41.77
$444.77K
Patrick J. Haley
20 Nov 2025
EVP, Commercial
Sell indirect
23,539
$41.93
$986.99K
Patrick J. Haley
20 Nov 2025
EVP, Commercial
Sell
10,000
$42.11
$421.10K
Stelios Papadopoulos
12 Nov 2025
Director
Sell
100,000
$43.55
$4.36M
Mary C Beckerle
11 Nov 2025
Director
Sold after exercise
18,838
$41.90
$789.31K
Mary C Beckerle
11 Nov 2025
Director
Sold after exercise
5,784
$42.03
$243.10K
Dana Aftab
11 Nov 2025
EVP, Research and Development
Sell
48,383
$42.50
$2.06M

What was left out

Form 4 filings counted 53
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 6
Sales straight out of an exercise 10
Sales at will 16
Transactions with no price 0
Shares from compensation/vesting 4,810,436
History held since 6 Oct 2006